The Distribution and Geographic Accessibility of Prostate Cancer Clinical Trials in the U.S.
Matthew D. Galsky, MD, from The Mount Sinai Hospital, discusses an analysis of the distribution and geographic accessibility of prostate cancer clinical trials in the U.S.
Clinical Pearls
Matthew D. Galsky, MD, associate professor, medicine, hematology and medical oncology, assistant professor, urology, The Mount Sinai Hospital, discusses an analysis of the distribution and geographic accessibility of prostate cancer clinical trials in the U.S.
- Classically defined barriers to enrollment on clinical trials have been patient awareness, acceptance of enrollment, and eligibility of enrollment
- Much less work has been done on the availability of cancer clinical trials
- This analysis aimed to answer the question of how far would an individual would have to travel to access their closest clinical trial site
- A large proportion of the population would need to travel greater than 30 miles to reach a cancer clinical trial site
- Greater than 30 miles has been used to characterize ‘high travel burden’ in previous studies
<<<
Novel Frontline Treatments Add Layer of Complexity in Urothelial Carcinoma
January 2nd 2025The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer and nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.
Read More
Cusnir Explores Impact of ARANOTE Data on ARPI Plus ADT Use in mHSPC
December 31st 2024During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they fit into the treatment paradigm for patients with metastatic hormone-sensitive prostate cancer.
Read More
